Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.110 | 0.500 | 0.390 |
Stocks | 99.890 | 99.890 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 18.510 | 15.320 |
Price to Book | 3.461 | 2.560 |
Price to Sales | 2.520 | 1.751 |
Price to Cash Flow | 12.041 | 9.863 |
Dividend Yield | 3.103 | 3.552 |
5 Years Earnings Growth | 10.467 | 8.650 |
Name | Net % | Category Average |
---|---|---|
Technology | 24.090 | 14.551 |
Industrials | 18.670 | 12.361 |
Financial Services | 18.460 | 18.371 |
Healthcare | 11.010 | 13.805 |
Consumer Cyclical | 10.700 | 8.247 |
Utilities | 6.640 | 5.735 |
Real Estate | 3.800 | 3.745 |
Consumer Defensive | 3.020 | 12.075 |
Communication Services | 2.600 | 6.604 |
Basic Materials | 1.020 | 4.069 |
Number of long holdings: 46
Number of short holdings: 17
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Edenred | FR0010908533 | 4.74 | 39.41 | -2.26% | |
Microsoft | US5949181045 | 4.74 | 446.95 | -1.30% | |
Broadcom | US11135F1012 | 4.43 | 1,605.35 | +1.18% | |
Merck&Co | US58933Y1055 | 4.31 | 123.77 | -4.66% | |
Terna | IT0003242622 | 3.93 | 7.218 | -1.66% | |
Novo Nordisk A/S Class B | DK0060534915 | 3.80 | - | - | |
Steadfast Group | AU000000SDF8 | 3.79 | 6.12 | -1.05% | |
Accenture | IE00B4BNMY34 | 3.73 | 303.41 | +0.07% | |
Taiwan Semiconductor | US8740391003 | 3.49 | 173.81 | +1.27% | |
Watsco | US9426222009 | 3.46 | 463.24 | +0.31% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Mirabaud Eq Glbl Focus A CHF Acc | 237.51M | -2.52 | -6.25 | - | ||
Mirabaud Glbl Eq HiIncome A CHF Acc | 69.69M | -0.23 | 2.51 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review